Vaxart (VXRT) Projected to Post Earnings on Thursday

Vaxart (OTCMKTS:VXRT) is expected to be issuing its Q2 2026 results after the market closes on Thursday, August 6th. Analysts expect the company to post earnings of ($0.12) per share and revenue of $26.2120 million for the quarter. Parties can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 7, 2026 at 4:30 PM ET.

Vaxart (OTCMKTS:VXRT) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.02 EPS for the quarter, hitting the consensus estimate of $0.02. Vaxart had a return on equity of 61.43% and a net margin of 14.51%.The firm had revenue of $39.23 million during the quarter, compared to analysts’ expectations of $50.50 million. On average, analysts expect Vaxart to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Vaxart Stock Up 1.7%

OTCMKTS VXRT traded up $0.01 during trading hours on Tuesday, hitting $0.60. 270,653 shares of the company were exchanged, compared to its average volume of 560,610. The company has a 50 day moving average of $0.56 and a two-hundred day moving average of $0.63. Vaxart has a 52-week low of $0.30 and a 52-week high of $0.84. The firm has a market cap of $145.70 million, a price-to-earnings ratio of 4.00 and a beta of 1.10.

Institutional Investors Weigh In On Vaxart

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new stake in Vaxart in the second quarter valued at $794,000. Jones Financial Companies Lllp grew its holdings in shares of Vaxart by 276,364.7% during the first quarter. Jones Financial Companies Lllp now owns 478,284 shares of the biotechnology company’s stock worth $196,000 after purchasing an additional 478,111 shares during the last quarter. Raymond James Financial Inc. grew its holdings in shares of Vaxart by 16.9% during the second quarter. Raymond James Financial Inc. now owns 236,166 shares of the biotechnology company’s stock worth $107,000 after purchasing an additional 34,075 shares during the last quarter. Invesco Ltd. increased its position in shares of Vaxart by 93.1% during the first quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company’s stock worth $60,000 after purchasing an additional 70,568 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Vaxart during the first quarter worth about $31,000. 18.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Zacks Research raised Vaxart to a “hold” rating in a research report on Thursday, July 9th. One analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, the company presently has an average rating of “Hold”.

About Vaxart

Vaxart, Inc is a clinical-stage biotechnology company pioneering the development of oral recombinant vaccines administered in tablet form. Leveraging a proprietary, room-temperature-stable platform, the company aims to simplify vaccine delivery while eliciting both systemic and mucosal immune responses. Its technology is based on the replication-defective adenovirus vector system, which encodes target antigens designed to protect against a range of infectious diseases without the need for injections or cold-chain logistics.

The company’s pipeline includes multiple vaccine candidates in various stages of development.